Eli Lilly Beats Q2 Earnings, Raises Full-Year Forecast on Weight Loss Drug Surge
On August 5, 2026, Eli Lilly announced a remarkable second-quarter revenue of $23.0 billion, marking a 48% rise compared to the same quarter last year. The pharmaceutical giant has also updated its full-year revenue projection to between $85 billion and $87 billion, an increase from the earlier estimate of $82 billion to $85 billion. This impressive growth is largely attributed to the soaring sales of its weight loss drugs. The company’s stock ticker is LLY. The positive earnings report and enhanced guidance indicate strong demand for its GLP-1 medications, which have emerged as blockbuster items, highlighting Eli Lilly's dominant role in the expanding weight loss treatment market.
Key facts
- Eli Lilly reported Q2 revenue of $23.0 billion, a 48% increase year-over-year.
- The company raised its full-year revenue forecast to $85-$87 billion from $82-$85 billion.
- Weight loss drug sales surged, driving the earnings beat.
- The announcement was made on Wednesday, August 5, 2026.
- Eli Lilly's stock ticker is LLY.
- The company's performance highlights strong demand for GLP-1 medications.
- The revised forecast indicates confidence in continued sales growth.
- The earnings report was covered by Quartz.
Entities
Institutions
- Eli Lilly
- Quartz
Sources
- Quartz —